EL7.AI
StocksMediumUpdated•Originally published 18 June 2026•Updated 18 June 2026•
1 min read

FDA Panel Recommends Approval for Moderna Flu Vaccine for Adults 50+

Key Facts

1The U.S. FDA advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults.

In a move that paves the way for diversifying its medical portfolio, Moderna has secured critical support from U.S. regulators for its new vaccine. The FDA advisory panel officially voted in favor of approving the company's mRNA-based flu vaccine, specifically recommending its use for adults aged 50 and older.

This regulatory victory follows clinical data showing the mRNA-1010 vaccine was 26.6% more effective than standard doses per NEJM findings (May 2026). Despite this progress, Jefferies analysts remain cautious regarding potential post-marketing requirements, while the stock faces valuation headwinds with a median price target of $45.00, trailing current market levels per market data.

Moderna (MRNA) closed at $61.80 (close June 17, 2026), with investors now shifting focus to the final FDA approval decision expected by August. Additionally, the market is monitoring the Michigan Consumer Sentiment index due on June 12 as a broader sentiment catalyst according to the economic calendar.